Eye Care

Besifloxacin ophthalmic suspension (Besivance) is indicated for the treatment of bacterial conjunctivitis.

But gene therapy may be the next big change; researchers recently identified a calcium modulator that protects the optic nerve in mice.

Pharmacists can play a key role in providing education and guidance to patients with glaucoma.

Fuchs' dystrophy causes fluid build up in the cornea, resulting in swelling.

Despite demonstrating numerous benefits, semaglutide has also been linked to an increased incidence of diabetic retinopathy, which was initially reported in the SUSTAIN-6 trial.

Blink Tears Lubricating Eye Drops maximizes hydration and restores tears’ natural salt balance.

Lotemax treats post-operative inflammation and pain following ocular surgery.

AzaSite is indicated for the treatment of bacterial conjunctivitis caused by CDC coryneform group G, Haemophilus influenzae, Staphylococcus aureus, Streptococcus mitis group, and Streptococcus pneumoniae.

Farsightedness usually is present at birth and tends to run in families.

Aflibercept is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

According to a press release from AbbVie, Vuity is the first and only FDA-approved eye drop to treat this condition, which affects nearly half of the US adult population.

According to the investigators, Susvimo is the first and only FDA-approved treatment for wet AMD that offers as few as 2 treatments per year.

Tafluprost acid, a prostaglandin analog, is a selective FP prostanoid receptor agonist that is believed to reduce intraocular pressure by increasing uveoscleral outflow.

As the first nasal spray for dry eye disease, varenicline solution nasal spray could be especially helpful for patients who have difficulty administering eye drops.

According to GenSight, GS030 combines AAV2-based gene therapy with optogenetics to treat RP.

According to Ocular Therapeutix, Dextenza is now the first FDA-approved, physician-administered intracanalicular insert capable of delivering a preservative-free drug for the treatment of ocular itching associated with allergic conjunctivitis with a single administration for up to 30 days.

Doctors and pharmacists discuss OTC and prescription treatment options and use during webcast.

An anti-vascular endothelial growth factor therapy, ranibizumab prevents vision loss in patients with retinal vascular disorders, which can cause irreversible blindness or visual impairments in adults.

The research team analyzed the associations between maternal diabetes before or during pregnancy and the risk of high refractive error (RE), which are conditions in which there is a failure of the eye to properly focus images on the retina.

According to the investigators, both trials demonstrated an overall well-tolerated safety profile for brolucizumab.

A panel of experts comment on new therapeutic agents being developed and discuss their final thoughts on dry eye disease.

Lisa M. Nijm, MD, JD, educates on Eysuvis, an FDA-approved prescription therapeutic for dry eye disease.

The panel discusses the possible prescription treatments for dry eye disease.

A panel of pharmacists and doctors explain when a patient should seek professional help for dry eye disease.

Top-line data from the NORSE TWO trial demonstrated that the treatment met the primary and key secondary endpoint for efficacy with clinically impactful change observed for treated patients.